# OnCo record axatilimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/axatilimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "axatilimab" ;
  schema:name "Axatilimab"@en ;
  schema:alternateName "axatilimab-csfr"@en, "Niktimvo" ;
  schema:description "Axatilimab targets an immune-cell signal used by macrophages. It is approved for chronic graft-versus-host disease and is being tested with olaparib in advanced breast cancer."@en ;
  schema:url <https://onco.cc/drugs/axatilimab/> ;
  schema:dateModified "2026-10-10"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb6dba23-e7a6-4765-a1e6-b9e277ce0381>, <https://clinicaltrials.gov/study/NCT06488378> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody" ;
  onco:approval "US 2024: Chronic graft-versus-host disease after failure of at least two prior systemic lines in adults and pediatric patients weighing at least 40 kg" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/> ;
  onco:targets <https://onco.cc/targets/csf1r/> ;
  onco:companies <https://onco.cc/companies/syndax/>, <https://onco.cc/companies/incyte/> ;
  onco:trials <https://onco.cc/trials/nct06488378/> .